Puma Biotechnology (PBYI) Receivables (2016 - 2026)

Puma Biotechnology's Receivables history runs 11 years deep, the most recent figure standing at $26.3 million for Q1 2026.

• Quarterly Receivables rose 2.26% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (up 2.26% YoY) and the FY2025 annual result came in at $53.7 million, up 67.61% from the prior year.
• Receivables was $26.3 million for Q1 2026 at Puma Biotechnology, down from $53.7 million in the prior quarter.
• Across five years, Receivables topped out at $55.4 million in Q3 2024 and bottomed at $25.6 million in Q1 2024.
• A 5-year average of $33.9 million and a median of $31.2 million in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables soared 91.22% — and 2025, when it plunged 39.42%.
• Puma Biotechnology's Receivables stood at $40.4 million in 2022, then rose by 18.56% to $47.8 million in 2023, then tumbled by 33.08% to $32.0 million in 2024, then jumped by 67.61% to $53.7 million in 2025, then tumbled by 50.93% to $26.3 million in 2026.
• Business Quant data shows PBYI's Receivables at $26.3 million in Q1 2026, $53.7 million in Q4 2025, and $33.6 million in Q3 2025.